Coda Octopus Group (CODA) Q4 2025 earnings review
Acquisition Masks Organic Stagnation, but Q4 Profits Surge
Coda Octopus posted a visually strong FY25 with revenue up 31% to $26.6M. However, this growth is primarily inorganic: the Precision Acoustics (PAL) acquisition contributed $5.4M of the $6.3M total increase. Organic growth remains anemic at ~4.4%. The bright spot is Q4 execution, where revenue jumped 44% YoY and operating income nearly quadrupled to $1.4M, driving margins expansion. While headline product numbers (DAVD, Echoscope) look robust, they cloak significant declines in legacy product lines.
🐂 Bull Case
Diver Augmented Vision Display (DAVD) sales more than tripled to $3.7M (vs $1.2M in FY24). The completion of the 'DUS Hardening Program' and delivery of 16 units to the U.S. Navy positions the tech for broader 'Authorization for Navy Use' (ANU).
Cash balance swelled to $28.7M (+27% YoY), representing roughly 45% of total assets. With zero long-term debt, CODA has significant dry powder for further M&A or R&D.
🐻 Bear Case
Stripping out the $5.4M revenue from the PAL acquisition, the legacy Marine and Defense segments grew only ~$0.9M (+4.4%) combined. The core business is barely moving the needle.
Management touted $4.7M in growth from Echoscope and DAVD, yet organic revenue only rose $0.9M. This implies nearly $3.8M in sales declines across other unspecified legacy product lines.
⚖️ Verdict: ⚪
Neutral. The Q4 profitability surge and DAVD momentum are promising, but the heavy reliance on an acquisition to drive top-line growth and the hidden decay in the legacy portfolio prevent a higher grade. The stock needs organic acceleration to verify the thesis.
Key Themes
Precision Acoustics (PAL) Acquisition Success
The PAL acquisition is the MVP of FY25. It contributed $5.4M in revenue (20% of total sales) and met all earn-out conditions. Without this unit, Coda's growth story would have been nearly flat. It also opens exposure to medical imaging and Non-Destructive Testing (NDT) markets.
DAVD Breakout Year
Sales of the DAVD system surged 208% to $3.7M. Critical milestones were hit: completion of the 'DUS Hardening Program' and delivery of 16 units to the U.S. Navy. The company identifies a TAM of 14,000 divers in the U.S. government/defense space alone, suggesting this driver has a long runway.
Hidden Decay in Core Portfolio
Management highlighted Echoscope growth (+$2.2M) and DAVD growth (+$2.5M). Mathematically, if these two specific lines grew by $4.7M, but the total organic business only grew by $0.9M, then other legacy products must have declined by approximately $3.8M. This 'churn' under the surface is a major red flag.
Gross Margin Compression
Gross margin fell from 69.8% to 66.5%. While still healthy, the decline reflects the mix shift from the PAL acquisition and geographical sales variance. As the business scales hardware deliveries (DAVD), margin preservation will be tested.
AI & Autonomy Pivot
The launch of the 'NANO Gen Series' sonar positions CODA for the autonomous vehicle market. Management is explicitly pivoting marketing language to 'perception sensors' for AI platforms rather than just data collection tools. Q4 trials were conducted specifically for AI-enabled decision support.
Defense Engineering Slowdown
The Defense Engineering Services business grew only 5.6% YoY ($7.9M vs $7.5M). Given the global geopolitical environment and increased defense spending, this single-digit growth lags the broader sector trend.
Other KPIs
Accelerating significantly. Q4 operating income jumped nearly 400% YoY, proving that once fixed costs are covered, the drop-through to the bottom line is powerful. Q4 operating margin hit 19.3%, well above the full-year average of 17.1%.
Stable/Accumulating. Up $6.2M YoY. The company is generating cash despite R&D investments ($2.4M) and acquisition integration costs. This strong balance sheet supports the 'ongoing task' of M&A mentioned by the CEO.
Stagnant. Up only 3.2% YoY. Considering this segment houses the flagship Echoscope and DAVD products (which reportedly grew fast), the sluggish topline suggests the legacy hydrographic survey market is dragging down results.
Guidance
Management did not provide specific numeric guidance. Qualitative commentary emphasizes 'momentum' and the Authorization for Navy Use (ANU) process as a catalyst for broader adoption. The 16 units delivered in FY25 are currently undergoing this approval.
Key Questions
Reconciling Product vs. Segment Growth
You reported strong growth in DAVD ($3.7M, +$2.5M YoY) and Echoscope ($9.4M, +$2.2M YoY). However, the Marine Technology segment only grew $0.4M total. Which specific product lines contracted by ~$4M to offset your growth drivers?
Timeline for ANU Approval
The 16 units delivered are undergoing Authorization for Navy Use (ANU). What is the typical duration for this process, and do you expect revenue recognition for follow-on orders to impact FY26 or is this an FY27 story?
M&A Strategy vs. Organic Investment
With organic growth at ~4% and a cash pile of $28M, are you prioritizing further acquisitions like PAL to drive topline, or do you see a path to double-digit organic growth in FY26?
Gross Margin Trajectory
Gross margins compressed ~330bps this year due to the PAL mix. Is 66-67% the new normal, or do you see a path back to 70% as DAVD volumes scale?